1 Magnesium (Mg)-de®cient rats develop a mechanical hyperalgesia which is reversed by a NMethyl-D-Aspartate (NMDA) receptor antagonist. Given that functioning of this receptor-channel is modulated by Mg, we wondered whether facilitated activation of NMDA receptors in Mg de®ciency state may in turn trigger a cascade of speci®c intracellular events present in persistent pain. Hence, we tested several antagonists of NMDA and non-NMDA receptors as well as compounds interfering with the functioning of intracellular second messengers for eects on hyperalgesia in Mg-de®cient rats.
Introduction
The magnesium (Mg)-de®cient rat is a new model of hyperalgesia (Dubray et al., 1997) . After a few days of consummation of a Mg-depleted diet, mechanical hyperalgesia develops in the rat which can be reversed by systemic injection of MK-801, a non-competitive antagonist of NMethyl-D-Aspartate (NMDA) receptors (Dubray et al., 1997) . Since many studies, over the last few years, have provided evidence that excitatory amino acid (EAAs) receptors play a signi®cant role in spinal nociceptive transmission and in the sensitization mechanism leading to hyperalgesia (Coderre & Melzack, 1991; Haley et al., 1990; Seltzer et al., 1991) , we assessed in our model the involvement of these EAAs receptors at the spinal level. NMDA and amino-3-hydroxy-5-methylisooxazole-4-propionic acid (AMPA) receptors, identi®ed as ionotropic receptors, belong to the family of EAA receptors (Dickenson, 1997a) . When a short painful stimulation is applied, AMPA receptors alone seem to mediate excitatory transmission and to set the baseline level of nociception, while NMDA receptors are not activated, as their channel is plugged by a physiological level of Mg (Mayer et al., 1984) . However, in chronic pain states, both receptors are probably involved. An intense stimulation of primary aerent ®bres initially activates AMPA and peptide receptors and, when frequency of stimulation exceeds threshold, the voltage-dependent Mg-block of NMDA receptors is removed, allowing activation of these receptors to take place (Mayer & Westbrook, 1987) . As a consequence, the opening of the NMDA receptor channel leads to an in¯ux of calcium (Ca 2+ ) into the neurons, triggering a cascade of intracellular events such as protein kinase C (PKC) activation (Mao et al., 1992b; Meller et al., 1996) or nitric oxide (NO) production (Meller & Gebhart, 1993) and ultimately immediate-early gene transcription (c-Fos; c-Jun) (Ren & Dubner, 1999; Woolf & Costigan, 1999) . NMDA receptors may also be modulated by peptides, like substance P (SP), which is released with glutamate from the primary aerent ®bres, to extend and maintain the nociceptive process (Liu et al., 1997; . All these events are responsible for the long-term changes associated with persistent pain (Coderre, 1993; Wong et al., 1995) . As demonstrated by in vitro studies, low Mg concentrations facilitate the opening of the Na + ± Ca 2+ channel of NMDA receptors (Mayer et al., 1984; Nowack et al., 1984; Zhang et al., 1996) . We may therefore presume that a dramatic decrease in Mg concentration in cerebrospinal¯uid (CSF) and in the brain of Mgde®cient rats (Chutkow & Meyers, 1968) may trigger the activation of NMDA receptors. The resulting increase in cytosolic Ca 2+ level would thereafter elicit a cascade of intracellular events responsible for the sensitization mechanism (Coderre & Melzack, 1991; Haley et al., 1990; Ren & Dubner, 1999; Seltzer et al., 1991) . In this present study, successive steps induced by NMDA receptor activation have been pinpointed as pharmacological targets. The aim of the present work, using intrathecal injection of antagonists, was to evaluate, at the spinal level, the involvement of the NMDA receptor and subsequent intracellular events in the induction of a spinal state of sensitization in the animal model of Mg-de®ciency-induced hyperalgesia.
Methods

Animals
Male Wistar rats (Charles River, France), weighing 90 ± 100 g, were used in all experiments. Rats were housed (n=4/ cage) in standard laboratory conditions with free access to food and water. The cages were equipped with a grid to prevent rats from eating their stools as that can modify the Mg-de®ciency induction.
Induction of the Mg-deficiency in rats
Animals were randomly divided into two groups, subsequently, for a 9-day period. The two groups of rats (depleted or normal) were allowed to feed ad libitum, either with the synthetic depleted diet (Mg-de®cient rats) or the control diet (control rats). Deionized water was also provided ad libitum during the same period.
The synthetic depleted diet contained (g kg ) to the mineral mix. The components were mixed together in an industrial mixer for 2 h. Finally, Mg concentrations in each diet, determined by¯ame atomic absorption spectrometric analysis (Perkin Elmer 400, Norwalk, CT, U.S.A.), were 35 and 980 mg kg 71 for the depleted and control diets, respectively.
Three additional groups of animals (n=5/group), submitted to the same depleted diet conditions than rats used for the behavioural studies, were used to check the Mg plasma level. Animals were anaesthetized with sodium pentobarbital (40 mg kg 71 of body weight, i.p.). Blood was collected from the abdominal aorta into heparinized tubes. Plasma obtained after low-speed centrifugation (20006g for 15 min) were stored in at 7208C until analysis. Mg plasma level was assessed by atomic absorption¯ame spectrometry (Perkin Elmer 400, Norwalk, CT, U.S.A.).
Nociceptive test
The antinociceptive eect of the tested compounds was assessed by using the paw pressure test previously described by Randall & Sellito (1957) . An increasing mechanical pressure was exerted by an analgesimeter (Apelex type 003920, Ugo Basil, Italy) on the left hind paw, until vocalization was elicited. This vocalization threshold was expressed in grams corresponding to the pressure applied. The cut-o value corresponded to the maximum pressure (500 g) allowed by the device after calibration for these experiments.
Behavioural testing
Behavioural observation allowed evaluating stereotypes (head weaving and circling, jerky movements, classed as absent or present) and global motor activity.
Drugs and chemicals
The following compounds have been tested: A non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist: dizocilpine maleate or (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5, 10-imine maleate (MK-801) (RBI, Sigma-Aldrich Co., Saint Quentin Fallavier, France) was dissolved in 0.9% NaCl (saline) on the day of experiment. Magnesium sulphate (MgSO 4 ) (Sigma-Aldrich Co., Saint Quentin Fallavier, France) was dissolved in saline. Two competitive NMDA receptor antagonists: D-2-amino-5-phosphono-valeric acid (AP-5) binding to the glutamate site (ICN Pharmaceuticals France, Orsay, France), was dissolved in saline and 5,7-dichlorokynurenic acid (DCKA) binding to the glycine site (RBI, Sigma-Aldrich Co., Saint Quentin Fallavier, France), was dissolved in 50% dimethyl sulphoxide (DMSO, Sigma-Aldrich Co., Saint Quentin Fallavier, France) (vehicle). A potent amino-3-hydroxy-5-methylisooxazole-4-propionic acid (AMPA)/kainate receptor selective antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (RBI, SigmaAldrich Co., Saint Quentin Fallavier, France) was dissolved in 50% DMSO. A potent PKC inhibitor, chelerythrine chloride (RBI, Sigma-Aldrich Co., Saint Quentin Fallavier, France) was dissolved in 10% DMSO. A selective inhibitor of brain nitric oxide synthase (nNOS), 7-nitro-indazole (7-NI) (RBI, Sigma-Aldrich Co., Saint Quentin Fallavier, France) had to be dissolved in arachis oil, justifying the intraperitoneal (i.p.) route. A neurokinin (NK) 1 receptor antagonist, SR-140333 (Sano® Recherche, Montpellier, France) was dissolved in 15% v v 71 DMSO +85% v v 71 saline and a NK 2 receptor antagonist, SR-48968 (Sano® Recherche, Montpellier, France) was dissolved in saline.
Injections
All drugs, except 7-NI, were injected intrathecally (i.t.) in the subarachnoid space between L5 and L6 vertebras according to Mestre et al. (1994) , under a transient volatile anaesthesia with 3.5% iso¯urane for 2 min. Behavioural testing commenced following a 5 min recovery period. The volume of the administered drugs was 10 ml. 7-NI was injected intraperitoneally in a volume of 5 ml kg
71
. 7-NI is a very lipophilic compound and crosses easily the blood-brain barrier (Babbedge et al., 1993; MacKenzie et al., 1994) .
Injections (i.t. or i.p.) of saline or vehicle were systematically performed in a control group of Mg-de®cient rats (saline or vehicle-treated group). In order to avoid any uncontrollable environmental in¯uence that could induce a change in the behavioural response, treatments were administered blind, with randomization procedure, using the method of equal complete blocks of animals. For each experiment, one block includes a number of animals equal to the number of treatments performed, each animal receiving a dierent treatment. The number of blocks corresponds to the eect of each treatment group (n=6 ± 8) of the experiment.
Experimental design
According to previous experiments with this model (Dubray et al., 1997) , each experiment took place 9 days after the introduction of the Mg-de®cient diet, when the mechanical hyperalgesia was clearly in place. At this time, in Mgde®cient or control matched age rats, the control values for hindpaw vocalization, taken as the mean of two consecutive stable values which do not dier more than 10%, were recorded just before injection of the tested drug at T0. Then, the eect of the drugs was assessed by recording the vocalization threshold at 15, 30, 45, 60, 90 and 120 min after injection. The experiments were carried out in a quiet room by the same investigator. We took care to avoid any discomfort of the animals. The protocol of the test was monitored by a local ethical committee. These experiments were conducted according to the guidelines of the Committee for Research and Ethical Issue of the I.A.S.P. (Zimmerman, 1983) . , n=8) on the time-course of the vocalization threshold of Mg-de®cient rats submitted to the paw pressure test (A). AUC was calculated throughout the period of 120 min for each dose in Mg-de®cient rats (B). Results are expressed as means+s.e.mean. *P50.05, **P50.01 and ***P50.001; compared to the saline-treated group of Mg-de®cient rats. , n=8/dose) or saline (10 ml rat 71 , n=8) on the timecourse of the vocalization threshold of Mg-de®cient and control rats submitted to the paw pressure test (A). AUC was calculated throughout the period of 120 min for each dose in Mg-de®cient rats (B). Results are expressed as means+s.e.mean. *P50.05, **P50.01 and ***P50.001; compared to the saline-treated group of Mgde®cient rats; +P50.05, ++P50.01, +++P50.001; compared to the saline-treated group of control rats. Coderre & Van Empel, 1994 and Nishiyama, 2000, respectively) , the highest doses used in Mg-de®cient rats were tested in normal rats (control group). DCKA (0.97, 9.7 or 97 nmol rat 71 , i.t.) (n=7/dose), a selective antagonist of glycine site (Corbett & Dunn, 1993; Kehne et al., 1991) and CNQX (0.9, 8.6 or 86 nmol rat 71 , i.t.) (n=6/dose) (Coderre & Van Empel, 1994) reported at these dose as no inducing side eect, were tested only in Mg-de®cient rats. All doses of drugs used in our experiments were chosen, according to the literature data, showing that they are able to induce an anti-hyperalgesic eect in dierent behavioural pain models (see references above and in Discussion).
Expression of results and statistical analysis
Data for the vocalization thresholds are expressed as mean+s.e.mean (standard error of the mean). Statistical signi®cance was assessed using a two-way analysis of variance (ANOVA) followed by a PLS Fischer's test to compare at each time point during the experiment, the value for the drug-treated group with the saline or vehicle-treated groups both in Mg-de®cient and in control rats. The signi®cance levels were: ***P50.001; **P50.01; *P50.05. To measure a global eect of the drugs, area under the time-course curve , n=8/ dose) or saline (10 ml rat 71 , n=8) (A) and DCKA, (0.97, 9.7, 97 nmol rat
71
, n=7/dose) or vehicle (10 ml rat 71 , n=7) (C) on the time-course of the vocalization threshold of Mg-de®cient and control rats submitted to the paw pressure test. AUC was calculated throughout the period of 120 min for each dose in Mg-de®cient and control rats (B,D). Results are expressed as means+s.e.mean. *P50.05, **P50.01 and ***P50.001; compared to the saline or vehicle-treated groups of Mg-de®cient rats.
(AUC) was calculated throughout the 120 min of the experimental period. Statistical analysis (t-test) was conducted between the drug-treated group and the saline or vehicle-treated group.
Results
In our present study, after 9 days of experimental diet, Mgde®cient rats displayed the expected decrease in Mg plasma concentration as previously described (Chutkow & Meyers, 1968; Dubray et al., 1997; Malpuech-BrugeÁ re et al., 2000) (0.17+0.01 mmol l
71
). This concentration was largely lower than this obtained in control rat (0.81+0.02 mmol l 71 ) in our previous study (Dubray et al., 1997) .
Effects of antagonists to EAA receptors and MgSO 4 on the hyperalgesia induced by Mg-deficiency in rats
The hyperalgesia observed in Mg-de®cient rats was dosedependently reversed by intrathecal injection of MK-801 (60 ± 0.6 nmol rat 71 ) ( Figure 1A) . A signi®cant (P50.001) anti-hyperalgesic eect was observed with the two highest doses (6 and 60 nmol rat 71 ) in Mg-de®cient rats, 15 min after drug injection (200.0+14.5 and 146.0+8.5 g respectively, in comparison with the saline-treated group, 91.1+6.5 g). No signi®cant eect was observed with the low dose (0.6 nmol rat 71 ) of MK-801. The AUC of the vocalization threshold con®rmed the dose-dependent antinociceptive eect of MK-801 ( Figure 1B) . However, in control rats, we did not observe any changes in either the behaviour of the animals or their vocalization threshold.
The intrathecal injection of MgSO 4 (6.6 ± 1.6 mmol rat 71 ) produced a dose-dependent elevation of the vocalization threshold in the Mg-de®cient group of animals (Figure 2A,B) . At the highest dose (6.6 mmol rat 71 ), MgSO 4 induced a signi®cant (P50.001) antinociceptive eect which peaked at 15 min after injection (417.1+40.9 g for the MgSO 4 -treated group vs 113.6+4.1 g for the saline-treated group) and persisted throughout the experiment. At doses of 4.8 and 3.2 mmol rat 71 , a signi®cant anti-hyperalgesic eect was also observed, with a maximum eect (P50.05) occurring 15 min after injection. The dose of 1.6 mmol rat 71 did not signi®cantly alter the vocalization threshold. At the highest dose (6.6 mmol rat 71 ), three out of eight animals presented for 15 min some signs of a bilateral motor weakness of the hind limbs but recovered fully thereafter. In contrast to their eects on the hyperalgesia in the Mg-de®cient group, it should be noted that the two highest doses of MgSO 4 did not change the vocalization threshold in control rats yet could , n=8/dose) or vehicle (10 ml rat 71 , n=8) on the time-course of the vocalization threshold of Mg-de®cient and control rats submitted to the paw pressure test (A). AUC was calculated throughout the period of 120 min for each dose in Mg-de®cient rats (B). Results are expressed as means+s.e.mean. *P50.05, **P50.01 and ***P50.001; compared to the vehicle-treated groups of Mg-de®cient rats.
cause motor eects. Thus, the positive eects on hyperalgesia in Mg-de®cient group of animals are not due to motor eects.
The intrathecal injection of two competitive antagonists of NMDA receptors, AP5 (162.3-10.2 nmol rat
) and DCKA (97 ± 0.97 nmol rat
) produced dose-dependent increases in vocalization threshold in Mg-de®cient rats (Figure 3) . At the highest doses, AP5 (162.3 and 40.6 nmol rat
) induced a signi®cant anti-hyperalgesic eect which peaked at 15 min after the injection (300.0+40.9 and 200.0+14.4 g, respectively). At these doses, neither change in the vocalization threshold, nor behavioural eect was observed in control rats ( Figure 3A,B) . No signi®cant eect was observed with the low dose (10.2 nmol rat 71 ) of AP5. The AUC of the vocalization threshold con®rmed the dose-dependent eect of AP5 ( Figure 3B) Figure 3C ). This dose-eect with DCKA was con®rmed with the AUC evaluation ( Figure 3D ). No side-eect was observed at any of the doses used in our study.
At the highest dose (86 nmol rat 71 ), CNQX, an antagonist of the AMPA receptors, produced a signi®cant (P50.001) increase in the vocalization threshold in Mg-de®cient rats ( Figure 4A ). The maximal value, 15 min after the injection, was 373.3+39.4 g (P50.001 vs 95.5+10.9 g for the vehicletreated group). This antinociceptive eect was con®rmed with the AUC value ( Figure 4B ). The low doses (8.6 and 0.9 nmol rat
) of CNQX as well as the vehicle, did not change the time-course of the vocalization threshold in Mgde®cient rats ( Figure 4A ).
Effects of inhibitors of PKC and nNOS on the hyperalgesia induced by Mg-deficiency in rats
Chelerythrine chloride (104.2 ± 1 nmol rat 71 ) reversed, dosedependently, hyperalgesia in Mg-de®cient rats ( Figure 5A ). The highest doses (104.2 and 10.4 nmol rat
71
) induced a signi®cant (P50.001 and P50.05, respectively) anti-hyperalgesic eect which peaked 15 min after the injection (221.6+29.7 g and 173.8+16.0 g, respectively). No eect was observed with the lowest dose of chelerythrine (1 nmol rat 71 ). These results were con®rmed with the AUC assessment ( Figure 5B ). It was important to note that the highest doses of chelerythrine and vehicle did not modify the time-course of the vocalization threshold in control rats ( Figure 5A ).
7-NI (150 ± 37.5 mmol kg
, i.p.) modi®ed the vocalization threshold ( Figure 6A ). At the highest doses, 7-NI produced a signi®cant (P50.001) anti-hyperalgesic eect which peaked at 30 min for the dose of 150 mmol kg 71 (185.7+16.4 g) and 15 min for the dose of 75 mmol kg 71 (184.9+11.7 g). This anti-hyperalgesic eect was con®rmed by the AUC values ( Figure 6B ). The dose of 37.5 mmol kg 71 and the vehicle did not change the vocalization threshold in Mg-de®cient rats. Furthermore, neither the dose of 150 mmol kg 71 nor the vehicle perturbed the time-course of the vocalization threshold in control groups ( Figure 6A ).
Effects of intrathecal antagonists to NK receptors on the hyperalgesia induced by Mg-deficiency in rats
At the highest dose (15 nmol rat 71 ), SR 140333, a NK 1 antagonist, was able to induce a signi®cant (P50.05) antihyperalgesic eect which appeared 15 min after injection (170.0+12.7 g) ( Figure 7A ). This signi®cant eect was con®rmed by calculating the AUC (P50.01 vs the vehicletreated group) ( Figure 7A ).
The intrathecal injection of NK 2 antagonist, SR 48968 induced only a weak signi®cant anti-hyperalgesic eect with 17 nmol rat 71 (158.6+12.9 g), at 15 min after injection (P50.05, vs the vehicle treated group, 115.0+4.2 g) ( Figure  7) . Although a small eect was observed with the paw pressure test, no eect was shown with the AUC (Figure 7D ), suggesting that SR 48968 did not markedly reverse the hyperalgesia in Mg-de®cient rats.
Discussion
In accordance with our previous results (Dubray et al., 1997) , the present data show that Mg-de®ciency in the rat is associated with a mechanical hyperalgesia. In parallel, no generalized change in behaviour (e.g. increase in spontaneous motor activity, tremors) which could induce false-positve hyperalgesia, was observed as previously noted (unpublished data). Spinal NMDA receptors are shown to be involved in this hyperalgesia, con®rming the established role of this receptor in pathophysiological pain processes, as described in many electrophysiological studies using neuropathic or in¯ammatory models (Stanfa & Dickenson, 1999; Suzuki et al., 2001) . (1) MK-801 inhibited the mechanical hyperalgesia in a dose-dependent manner, whereas it had no eect in the control group. In several models of neuropathic pain, both systemic (Davar et al., 1991; Smith et al., 1994; Wei & Pertovaara, 1999) and intrathecal MK-801 (Chaplan et al., 1997; Mao et al., 1992a, c; Sotgiu & Biella, 2000; Yamamoto & Yaksh, 1992a ) also reduce hyperalgesia; it is eective in the NMDA dependent phase of the formalin test (Coderre & Melzack, 1992; NaÈ sstroÈ m et al., 1992; Yamamoto & Yaksh, 1992b) and in other in¯ammatory pain models (Ren et al., 1992) . (2) The intrathecal administration of MgSO 4 in de®cient rats induced an anti-hyperalgesic eect which illustrates that the hyperalgesia induced by Mg-de®ciency is reversible and con®rms, on the basis of the Mg-block of the channel of the ionotropic NMDA receptor, the involvement of spinal NMDA receptors in this hyperalgesia. The highest dose produced a transient paralysis in some in Mg-de®cient rats as reported by Ishizaki et al. (1999) and Karasawa et al. (1998) ; the limited duration of the motor dysfunction means it cannot account for the anti-hyperalgesia. Our results are consistent with other behavioural studies: Ishizaki et al. (1999) and Takano et al. (2000) , showing that similar intrathecal doses of MgSO 4 suppress the NMDA receptor-dependent phase 2 of the formalin test; Begon et al. (2000) and Xiao & Bennett (1994) , showing that systemic or intrathecal Mg injections have an anti-hyperalgesic eect in animal models of neuropathic pain. (3) The anti-hyperalgesic eect of AP-5 or DCKA (competitive antagonists of glutamate and glycine site of NMDA receptors, respectively), which have been shown to abolish NMDA induced wind-up of dorsal horn nociceptive neurons (Dickenson & Aydar, 1991; Haley et al., 1990; Rygh et al., 2001) , further supports the involvement of these receptors in the hyperalgesia induced by Mg-de®ciency. Although Mg-de®ciency very likely facilitates the opening of the NMDA receptor channel, this mechanism is clearly still dependent on the presence of glutamate and glycine at their respective binding sites.
Moreover, it should be noted that AP5, DCKA, and the higher doses of MgSO 4 were also anti-nociceptive in the de®cient animals. There was an overshoot of the response to the paw pressure test above control values. This would suggest that the depletion of Mg causes a sequence of events that allows the NMDA receptor to participate in the basal neuronal activity, as well as contributing to hyperalgesia. Exogenous MK-801 however, was only anti-hyperalgesic. This dierence between the drug and the cation may arise from variations in the potency, ecacy, voltage-dependency and unblocking kinetics (MacDonald & Nowack, 1990 ) in the formalin test. However, high doses of CNQX lose speci®city and block the strychnine-insensitive glycine site of NMDA receptors (Birch et al., 1988) , which could contribute to the observed antihyperalgesic eect of CNQX.
The dose-dependent anti-hyperalgesic eect induced by intrathecal injection of chelerythrine, a PKC inhibitor, suggests that this enzyme, one of the key intracellular events after NMDA activation (Coderre, 1993; Mayer & Miller, 1990) , is involved in Mg-de®ciency-induced hyperalgesia. Interestingly, similar doses of chelerythrine are eective in various models of hyperalgesia (intrathecal NMDA injection, Meller et al., 1996; formalin test, Yashpal et al., 1995 or intraplantar injection of bee venom, Li et al., 2000) which con®rms that Mg-de®ciency induces an hyperalgesia due to a similar PKC-dependent mechanism. A recent electrophysiological and behavioural study on PKCg-null mice, con®rms that PKC is strongly involved in the long-term NMDA-dependent activity, and is notably required for the hyperexcitability in deep cells of spinal cord (Martin et al., 2001) , which is in line with the prolonged hyperalgesia observed in Mg-de®cient rats.
The anti-hyperalgesic eect of 7-NI, a speci®c neuronal NOS inhibitor (MacKenzie et al., 1994; Moore et al., 1993a, b) , in Mg-de®cient rats, is evidence for a pivotal role of NO in this hyperalgesia. NO is thought to be produced in response to NMDA receptor activation (Garthwaite et al., 1989) , and plays an important role in nociceptive processing in the spinal cord (Meller & Gebhart, 1993) . Stanfa et al. (1996) demonstrated that 7-NI blocked the wind-up of dorsal horn neurons after carrageenan in¯ammation. In the formalin test, NOS inhibitors suppress the chemical second phase (Haley et al., 1992; Malmberg & Yaksh, 1993) . Therefore, if we consider that the Mg-de®ciency produces an activation of spinal NMDA receptors and as a consequence induces a cascade of events involving NOS, we can assume that NO participates in a positive feedback mechanism enhancing the release of glutamate and SP from primary aerent terminals (Garry et al., 1994; Sorkin, 1993) .
The limited reduction of mechanical hyperalgesia in Mgde®cient rats by SR-140333 and to a lesser extent by SR-48968, suggests a weak involvement of these NK 1 and NK 2 receptors and their endogenous ligands in hyperalgesia due to Mg-de®ciency. These two compounds were shown more eective than here, on mechanical hyperalgesia observed in diabetic and mononeuropathic rats (Coudore-Civiale et al., 1998) , suggesting pathophysiological dierences in the spinal involvement of SP and neurokinin A according to the aetiology of the hyperalgesia.
Conclusion
The present data clearly show, for the ®rst time, that Mgde®ciency-induced hyperalgesia is linked to the activation of spinal NMDA receptors and to the cascade of ensuing intracellular changes. They consolidate the hypothesis that this hyperalgesia results from altered regulation of these receptors by Mg-de®ciency, and suggest a sensitization of spinal dorsal horn neurons needing to be further explored by an electrophysiological approach.
